Mumbai, Johannesburg, October 4, 2024: Global pharma major Lupin Limited (Lupin) today announced that its South African subsidiary, Pharma Dynamics, has acquired nine brands along with their associated trademarks, from the Medical Nutritional Institute SA (MNI) in South Africa, through a partnership deal with ImpiloVest, a South African investment firm.

The acquired brands include AntaGolin, RyChol, NeuroVance, SkinVance, FlamLeve, Rheumalin, SleepVance, ImmunoVance, and OviVance. These products cater to a range of health issues such as metabolic syndrome, insulin resistance, cognitive function, skin health, inflammation, joint care, sleep quality, immune support, and women’s hormonal well-being.

MNI is dedicated to developing and offering phytochemical (plant-based) products and healthcare solutions, aimed at treating metabolic syndrome. This acquisition will enable Lupin gain access to MNI’s wide portfolio of nine brands, that are marketed as branded products in the South African retail sector.

Thierry Volle, President EMEA, Lupin said, “This acquisition is a major step for Lupin to expand our footprint in the Complementary and Alternative Medicines sector. MNI’s innovative plant-based products align perfectly with our goal to provide holistic and sustainable healthcare solutions to our patients in South Africa.”

Erik Roos, CEO, Pharma Dynamics said, “There is a growing trend of patients seeking proactive healthcare solutions. This acquisition broadens our product range by concentrating on metabolic diseases such as cardiovascular disease, diabetes, and neuroscience, thereby enhancing patient health and well-being.”

Mariaan du Plessis, CEO of MNI, shared her excitement about joining Pharma Dynamics. “We are proud to partner with a company that shares our dedication to holistic and preventive healthcare. MNI’s unique plant-based formulations, developed in 2002 by a team of healthcare professionals, have been extensively tested to ensure their efficacy.”

About Lupin
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 22,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.
To know more, visit www.lupin.com or follow us on LinkedIn https://www.linkedin.com/company/lupin

For further information or queries please contact –

Rajalakshmi Azariah
Vice President & Global Head – Corporate Communications, Lupin
rajalakshmiazariah@lupin.com